CEO, Reflexion Pharmaceuticals
Beyond Antibodies: Advantages of fully synthetic mirror image proteins as drug molecules
Dana Ault-Riché has started five different biotechnology companies, in each case serving as the CEO for the company. Reflexion Pharmaceuticals is the leader in the development of D-proteins, an innovative new class of pharmaceutical products. Zyomyx was the first protein microarray company and pioneered the development of nanostructured devices with specialized surfaces for protein attachment and testing. Pointilliste pioneered the development of high-content protein microarrays that could be interrogated by living cells. Diazyme develops a wide range of new clinical diagnostic tests. AllChemie focused on the development of novel peptidomimetic medicines for the treatment of diabetes. Dr. Ault-Riché received a PhD from the University of Kansas and completed postdoctoral training at Stanford University with Nobel laureate Arthur Kornberg.